Mithra logo.jpg
Mithra sells shares in Mayne Pharma
15 févr. 2024 12h23 HE | Mithra Pharmaceuticals
          Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra,...
Mithra logo.jpg
Mithra updates on cash position
06 févr. 2024 01h00 HE | Mithra Pharmaceuticals
          Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with...
Mithra logo.jpg
Mithra updates on cash position
06 févr. 2024 01h00 HE | Mithra Pharmaceuticals
          Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with...
Mithra logo.jpg
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
21 déc. 2023 11h45 HE | Mithra Pharmaceuticals
          Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the...
Mithra logo.jpg
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
20 déc. 2023 11h45 HE | Mithra Pharmaceuticals
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
Mithra logo.jpg
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial
18 déc. 2023 01h00 HE | Mithra Pharmaceuticals
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program...
Mithra logo.jpg
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
04 déc. 2023 01h00 HE | Mithra Pharmaceuticals
          Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter...
Mithra logo.jpg
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
30 nov. 2023 01h00 HE | Mithra Pharmaceuticals
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States DONESTA® for the treatment of vasomotor symptoms of menopause, is expected to target...
Mithra logo.jpg
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam
28 nov. 2023 11h45 HE | Mithra Pharmaceuticals
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam Five abstracts on the positive effect of E4 accepted for oral...
Mithra logo.jpg
Mithra’s NEXTSTELLIS® granted additional patent in the United States
07 nov. 2023 01h00 HE | Mithra Pharmaceuticals
                                                          Mithra’s NEXTSTELLIS® granted additional patent in the United States New patent extends protection for NEXTSTELLIS® (ESTELLE®) until...